Specialized Growth Hormone Antagonist Compositions for Niche Environments
Legal Citation
Summary of the Inventive Concept
The inventive concept relates to novel growth hormone antagonist compositions and systems adapted for specific, narrow market or unique operational environments, such as high-security needs, disaster relief, or extreme weather conditions.
Background and Problem Solved
The original patent disclosed a combination therapy for treating cancer and other diseases using a modified human growth hormone receptor antagonist. However, the original patent did not address the need for specialized compositions and systems tailored to specific, high-stakes environments. The new inventive concept addresses this limitation by providing compositions and systems that can effectively treat cancer in high-security environments, disaster relief scenarios, extreme weather conditions, remote or isolated areas, and high-altitude environments.
Detailed Description of the Inventive Concept
The new inventive concept comprises modified human growth hormone receptor antagonist compositions and systems that incorporate specialized features for specific environments. For example, Claim 1 discloses a system for treating cancer in high-security environments, featuring a secure data transmission module for transmitting treatment data to authorized personnel. Claim 2 discloses a method for treating cancer in disaster relief scenarios, involving rapid deployment of a modified human growth hormone receptor antagonist in emergency situations. Claim 3 discloses a composition for treating cancer in extreme weather conditions, featuring a temperature-stable packaging system for maintaining potency in extreme temperatures. Claim 4 discloses a system for treating cancer in remote or isolated areas, featuring a satellite communication module for transmitting treatment data to remote healthcare providers. Claim 5 discloses a method for treating cancer in high-altitude environments, involving formulation of the modified human growth hormone receptor antagonist to mitigate the effects of high altitude on treatment efficacy.
Novelty and Inventive Step
The new inventive concept is novel and non-obvious in that it provides specialized compositions and systems that address the unique challenges of specific, high-stakes environments. The incorporation of secure data transmission modules, rapid deployment formulations, temperature-stable packaging systems, satellite communication modules, and high-altitude formulations constitutes a significant inventive step beyond the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include compositions and systems adapted for other niche environments, such as space exploration, underwater operations, or extreme humidity conditions. Variations could also include different types of cancer or diseases treated, different dosing regimens, or different modes of administration.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of oncology and emergency medicine. The target market includes healthcare providers, pharmaceutical companies, and government agencies operating in high-stakes environments.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/27 |
| A | A61 | A61K45/06 |
| A | A61 | A61K47/10 |
| A | A61 | A61P35/00 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and pharmaceutical compositions, specifically focused on growth hormone receptor antagonists for cancer treatment, requiring advanced knowledge of protein engineering, drug formulation, and oncological therapeutic strategies
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with a PhD in biotechnology or pharmaceutical sciences, expertise in protein modification, drug delivery systems, and cancer treatment methodologies, familiar with receptor antagonist design and polyethylene glycol conjugation techniques
Obviousness Rationale
A person having ordinary skill would recognize that the published technical disclosure represents predictable variations of the source patent's core technology by applying known biotechnological techniques to modify drug delivery and treatment contexts. The fundamental molecular structure of the growth hormone receptor antagonist remains substantially unchanged, with the variations primarily addressing contextual and environmental deployment challenges. These modifications represent standard engineering approaches for adapting pharmaceutical compositions to specific use scenarios.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,602 |
|---|---|
| Title | Growth hormone antagonist and anti-cancer composition combination therapy |